Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with
limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and
thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma.
fb-PMT also is actively transported across the blood-brain barrier into the brain. This study
is being conducted to determine the dose level for further clinical development of fb-PMT to
treat recurrent Glioblastoma.